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Summary
Serum beta-2-microglobulin (82m) concentrations were
determined in 43 southern African black patients with multiple
myeloma (MM), in 130 black patients with monoclonal
gammopathy of undetermined significance (MGUS) and in 70
control subjects. The results showed median values for serum
82m in patients with MM, MGUS and the control group to be
8,10 mgll, 3,05 mg/l, and 2,35 mg/l, respectively; these
values differed significantly from one another (P< 0,(1), even
when patients with normal renal function (serum creatinine
value < 110 Jlmolll) were considered separately. The median
_serum 82m concentration for IgG MM (22 cases) was 4,3
mgll, for IgA MM (8 cases) 7,3 mgll, and 24,2 mg/l for
Hence Jones MM (12 cases). These differences were also
significant (P = 0,001), but not in the restricted group of MM
patients with normal -renal function. In the 43 MM patients
serum 82m concentrations had a significant positive corre-
lation with serum creatinine (r = 0,706; P < 0,005) and a
significant negative correlation with haemoglobin values (r =
-0,459; P = 0,006). In 28 MM patients with normal renal
function, serum ~m values had a significant negative corre-
lation with serum albumin (r = -0,602, P = 0,003). Sixty-five
per cent of the 43 MM patients and 18,5% of the MGUS
patients had raised serum 82m values (> 4,7 mgll). An
optimum cut-off value for serum 82m of 6,9 mg/l for-differen-
tiating MM from MGUS was determined using a classification
rule. Despite lacking specificity, serum 82m measurement
was useful in differentiating MM from MGUS, and was the
best second choice variable in relation to serum albumin and
haemoglobin in patients with normal renal function.
S Air Med J 1991; 79: 650-653.
Beta-2-microglobu1in (B2m), a polypeptide with a molecular
weight of 11,815 daltons, occurs as the free light-ehain portion
of the major histocompatibility complex (MHC) class I antigen
of man (HLA) and other vertebrates.' It is present on the
cytoplasmic membranes of nearly all nucleated cells, as well as
in certain body fluids such as serum, urine, and cerebrospinal
fluid.2
Increased levels of serum B2m have been observed in asso-
ciation with lymphoproliferative disorders, such as chronic
lymphocytic leukaemia; some lymphomas, as well as multiple
myeloma (MM).3 However, certain benign diseases, such as
rheumatoid arthritis, systemic lupus erythematosus and viral
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infections, are also associated with raised serum B2m concentra-
tions.4 Furthermore, serum B2m levels are not only raised due
to increased rates of synthesis, but also in patients with renal
disease associated with a diminished glomerular fJ.ltration rate.5 .
Three reports6- S of serum B2m concentrations in MM and
monoclonal gammopathy of undetermined significance
(MGUS) have appeared, although the total number of patients
analysed was smaller than in this study. Only one studYS
analysed the concentrations of serum B2m in MM patients in
relation to both normal and abnormal renal function.
In the present study the usefulness of serum B2m in differen-
tiating MM from MGUS was evaluated, with particular
emphasis on the influence of renal function in these patients.
In addition, the correlation coefficients between serum B2m
and serum creatinine, serum albumin, and haemoglobin values
were determined in both MM and MGUS patients, who were
also divided between abnormal and normalrenal status.
Patients with MM were all initially seen at advanced stages
of this malignant disease and were analysed as one group. In
consequence, a specific comparison between seruI)l B2n1 values
in patients with low cell mass MM (grade I) and MGUS
could not be made.
Patients and methods
The patient group consisted of 173 southern African black
patients with monoclonal gammopathies. The differentiation
between benign and malignant disease was made by accepted
clinical, radiological, haematological and biochemical criteria.9
Forty-three patients were diagnosed as having MM, of which
17 had renal impairment (serum creatinine level> 110 pmoVl).
Out of 130 patients with MGUS, 32 had raised serum creati-
nine values (> 110 pmoVl). The control group consisted of 70
age-matched patients with normal renal function, attending an
epilepsy clinic. Sera from MM patients were obtained before
treatment.
Assay methods. Sera-obtained for B2m estimation in the
different groups were stored at -20°C until analyses were
performed. The concentrations of B2m were assayed in dupli-
cate utilising a commercially available solid phase radio-
immunoassay (phadebas P2-microtest, Pharmacia, Uppsala,
Sweden). The normal reference range for the 70 control
subjects was 0,7 - 4,6 mg/l (mean ± 2 SD). Serum creatinine
concentrations were determined with a continuous flow analyser·
(SMA II, Technicon Corp., Tarrytown, N.Y.) utilising the
Jaffe reaction. Serum albumin levels were determined by the
same instrument using the bromocresol-green method. Haemo-
globin levels were determined oothe Technicon HI (Teehnicon
Corp.). . .
Statistics. The non-parametric Mann-Whitney U-test was
used to test for a significant difference between the median
B2m values for MM, MGUS and control subjects. Sub-types
of MM were tested for significant differences in median serum
B2m levels by means of the Kruskal-Wallis test. Spearman
correlation coefficients were used to evaluate the correlation
between serum B2m ievels and other serum analytes measured.
The technique known as classification trees'O was used -to
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TABLE I. MEDIAN SERUM B,m CONCENTRATIONS (mgll) IN PATIENTS (MM AND MGUS) AND
CONTROL GROUP
No. of "
Disease patients Median (range) 25th percentile 75th percentile
MM
All cases 43 8,10 (2,10 - 56,0) 3,55 18,8
serum creatinine « 110 JLmolJl) 25 4,10 (2,60 - 22,5) 2,60 7,80
MGUS
All cases 130 3,05 (0,40 - 16,0) 2,30 4,30
serum creatinine « 110 JLmolJl) 98 2,80 (0,40 - 13,6) 2,30 3,70
Control group 70 2,35 (1,5 - 5,90) 2,0 3,0
derive a rule for classifying MM and MGUS patients. Confi-
dence intervals (Cl) (95%) for serum B2m concentrations in
MM and MGUS patients were calculated based on the means.
Results
The range, median, 25th and 75th percentile values for serum
B2m in the patient and control groups. are shown in Table I,
and the 95% Cl for serum B2m values based on the means in
both patient groups are shown in Table 11. The differences
between the median values for MM, MGUS and control
patients were significant when considering all the patients
(P < 0,01 for all comparisons), as well as those with serum
creatinine levels < 110 JLmoVl (normal renal function). In the
res~eted group with normal renal function MM patients had
a significantly higher serum B2m median value than the MGUS
patients (P = 0,003) and the controls (P < 0,0005), and the
MGUS patients, in turn, had a significantly higher median
than the controls (P = 0,009).
The median serum B2m values for patients with various
myeloma sub-types (Table Ill) differed significantly
(P = 0,001). However, when patients with renal impairment
were excluded in this group, the difference in median v3J.ues
was not significant (P = 0,174).
Correlation between serum B 2m values and
other measured analytes in monoclonal
gammopathies
The Spearman correlation coefficient (r) for serum B2m and
TABLE 11. 95% Cl FOR SERUM B2m CONCENTRATIONS




All cases 43 9,3 - 17,4
Serum creatinine « 110 JLmolll) 25 4,1-8,1
Serum B2m (> 4,7 mgll) 28 13,8 - 24,0
Serum B2m (> 4,7 mgll with
serum creatinine < 110 JLmolJl) 11 7,2 - 13,3
Serum B2m (> 6,9 mgll) 25 15,1-25,9
Serum B2m « 6,9 mgll) 18 2,8 - 4,1
MGUS
All cases 130 3,3 - 4,2
Serum creatinine « 110 JLmolJl) 98 2,9 - 3,6
Serum B2m (> 4,7 mgll) 25 6,5 - 9,0
Serum B2m (> 4,7 mgll with
serum creatinine < 110 JLmolll) 11 5,3 - 8,6
Serum B2m (> 6,9 mgll) 10 8,8 - 12,8
Serum B2m « 6,9 mgll) 120 2,9 - 3,4
serum creatinine levels in the MM patients was 0,706 (P <
0,0005), but only 0,141 in those patients with normal renal
function (not significant). There was also a significant negative
correlation in the 43 MM patients between serum B2m and
haemoglobin levels (r = -0,459; P = 0,006). In the 28 MM
patients with normal renal function the only significant rmding
TABLE Ill. SERUM B,m LEVELS (mgll) IN MM SUB-TYPES'" (ALL CASES)
No. and light 25th 75th
Myeloma sub-type chain type Median percentile percentile
IgG 22 4,3 2,5 8,4
(12'\)
(10'\)
IgA 8 7,3 4,7 13,2
(4'\)
(4K)
BenceJones 12 24,2 13,6 35,0
(3'\
(9K)
IgD 1 Single value of 51,0
(,\)
Non-secretor IgA 1 Single value of 3,2
(K)
·W.edian values for myeloma sub-types studied differed significan~y (p= 0,(01).
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Discussion
Fig. 1. Classification rule for differentiating MM and MGUS (all
cases).
Fig. 2. Classification rule for differentiating MM and MGUS in
patients with normal renal function.
Serum (j2-~icroglobulin (mg/!)
tively, in each of these earlier reports compared with 4,7 mgll
in the southern Mrican blacks in the present study. The
explanation for the higher circulating B2m in black subjects is
not known, but it may be related to increased chronic exposure
to certain infectious agents, particularly Mycobacterium tuber-
culosis, resulting in lymphocyte or macrophage stimulation and
increased B2m synthesis.4
In this study 28 of the MM patients (65%) had raised serum
B2m values (> 4,7 mgIl) and of these, 11 had normal renal
function. Of the MGUS patients, 24 (18,5%) had raised
values, of which 8 patients had normal renal function. This
agrees well with the results of previous investigations where
between 39% and 74% of MM patients were reported to have
increased B2m levels.
6
,ll,12 In our MM patients 39,5% had
raised serum creatinine concentrations, compared with·29% in
Morrell and Riesen's6 study. The higher incidence of renal
impairment in our MM patients may partly explain the higher
median serum B2m value (8,1 mgll) obtained, which is also
related to the fact that our patients present at a much later
stage of disease.
In the present study a significant difference was noted
between the median serum B2m levels in MGUS patients and
the control group. Furthermore, a significant difference in the
median serum B2m concentrations for the MM dif"t:rent
immunoglobulin classes analysed was observed, but not when
comparing MM patients with normal renal function as a
separate group. Various studies have failed to establish such a
statistically significant difference/,6,Il,12 but only Kin et al. 12
clearly defIned their MM patient group as having normal renal
function. The highest serum B2m concentrati~ns in our 43
MM patients were associated with Hence Jones MM, followed
by IgA and IgG MM. This may be explained by the fact that
some Hence Jones MM cases are associated with a-more rapid
onset of tubular and ultimately glomerular damage,13 resulting
in a reduced glomerular ftltration rate and diminished clearance
of B2m. Serum B2m concentrations for single cases of an IgDA
and an IgAK non-secretor MM were 51,0 mgll and 3,2 mgll,
respectively. These values are in accordance with the relatively
short survival time for patients with IgD MM14 and the longer
survival time for non-secretor MM patients who have a lower
tumour mass at presentation.15
Serum B2m and creatinine levels showed a significant corre-
lation in all MM and MGUS patients, reflecring the effect of
renal _impairment on lowering the glomerular ftltration rate,
thereby raising serum B2m and creatinine concentrations. A
significant negative correlation between serum B2m and haemo-
globin was observed in the 43 MM patients, but not in MM
patients with normal renal function. This froding is obscure,
but could imply that the anaemia" associated with MM in the
more advanced stages of disease is more significantly related to
renal complications, such as low erythropoietin production,
than to increased tumour cell mass and bone marrow replace-
ment alone. The significant negative correlation between serum
B2m and the serum albumin was observed only in th~ MM
patient group with normal renal function. This observation
seems paradoxical, since one would have also .expected a
significant correlate when considering all 43 MM patients.
There is no apparent explanation for this froding.
Using a cut-off value for serum B2m concentrations of 4,6
mgll, the diagnostic sensitivity for MM in our patient popula-
tion group was 65,5%, but 24 out of 130 MGUS patients
(18,5%) would be falsely classifIed as MM. By means of the
classifIcation tree rule an optimum cut-off value "of 6,9 mgll
for serum B2m was derived for differentiating MM patients
(irrespective of clinical stage and renal function) from MGUS
patients. The resultant sensitivity using this value for MM was
58,1%, but the specifIcity rose to 91,5%.
In conclusion, it can be seen mal serum n2m value lacks


















was a negative correlation between serum B2m and albumin
(r = -0,602; P = 0,003).
In the 130 patients with MGUS, the only significant corre-
lations were between serum B2m and creatinine values (r =
0,393; P = 0,0001) and a negative correlation with serum
albumin level (r =-0,237; P = 0,008).
Classification rule for differentiating
MMfromMGUS
The classifIcation rule, using all the data for MM and
MGUS patients (Fig. 1), indicated an optimum cut-off value
for serum B2m of 6,9 mgll for differentiating between the two
conditions (diagnostic sensitivity 58,1%, specifIcity 91,5%).
When considering only patients with normal renal function,
the haemoglobin and serum albumin levels were the preferred
determinants (Fig. 2). Using this classifIcation rule for differen-
tiating MM from MGUS, a diagnostic sensitivity of 88% and a
speciftcity of 70% for MM was obtained. B2m, however,
remains the best second choice variable for both haemoglobin
and albumin in the classifIcation tree as a predictor.
The serum B2m concentration in healthy white subjects was
reported to be 1,1 - 2,4 mgll (mean ± 2 SD) in one study6 and
0,84 - 2,76 mgll in a second.7 The uppe'r limit of normal ior
serum B2m level was taken as 2,4 mgll and 3,0 mgll, respec-
can be useful in differentiating MM patients considered
globally from MGUS in southern Mrican black patients.
When considering MM patients with normal renal function,
this differentiation can be better accomplished by measuring
serum haemoglobin and albumin values with serum B
2
m as
the best second choice variable. Futtbermore, the various MM
immunoglobulin classes show a significant difference in the
median serum B2m values· when patients with abnormal-renal
function are included in the analysis.
We wish to thank Mrs E. Kleynhans for typing the manuscript.
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Intradermal vaccination against hepatitis B
in a group of medical students
N. S. BRINK, A. B. MURRAY
Summary
A prospective study of a low-dose (one-tenth) intradermal
regimen using recombinant hepatitis B vaccine was under-
taken during two consecutive years in 4th-year medical stu-
dents. Eightj;one per cent of the vaccinees (123/152) sero-
converted with anti.HBs levels of> 10 lUll. The lower titre of
hepatitis B surface antibodies compared with published
studies on intramuscular immunisation, together with a sero-
conversion rate of only 81%, makes the intradermal method,
in our opinion, a suboptimal form of hepatitis B immunisation.
S AIr Med J 1991; 79: 653-654.
The prospect of administering a course of low-dose (one-
tenth) hepatitis vaccine intradermally instead of a full dose
intramuscularly is attractive in view of the potential cost
saving. The immunogenicity of hepatitis B vaccine administered
via the intradermal route has been demonstrated in several
studies, with seroconversion rates varying from 83% to 92%. I-3
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One recent study3 comparing intradermal and intramuscular
hepatitis B vaccination in individuals matched for age and sex
showed comparable seroconversion rates in both groups.
Since medical students form part of tb' ~ealth care team,
they are occupationally exposed and should be immunised
against hepatitis B. A major consideration in the administration
of a hepatitis B vaccination is the cost of the vaccine.
Subjects and methods
Volunteers from two consecutive classes of 4th-year medical
students were vaccinated with 2 JLg (0,1 ml) of hepatitis B
vaccine intradermally at 0, 1 and 6 months. Serum was
obtained for the determination of hepatitis B surface antibody
(anti-HBs) status before immunisation and 6 - 8 weeks after
completion of the vaccination course. Informed consent was
obtained from all participating students and it was indicated
that a full dose (20 JLg) of hepatitis vaccine would be given by
intramuscular injection to non-responders. Vaccine was
administered by medical practitioners and great care was taken
to ensure that successful intradermal inoculation was achieved
in all students.
A recombinant hepatitis B vaccine, Engerix B (Smith, Kline
and French), was stored at 4°C.
Anti-HBs levels were determined by radio-immunoassay
(Ausab, Abbot Laboratories, North Chicago). A linear corre-
lation coefficient > 0,9 allowed extrapolation to international
units per litre (IU/I). Seroconversion was defmed as greater
than 10 lUll. Non-responders receiving 20 JLg of hepatitis B
